Status:

WITHDRAWN

Study Using Pharmacogenetics to Select Treatment for Head and Neck Cancer

Lead Sponsor:

Georgetown University

Conditions:

Head and Neck Cancer

Eligibility:

All Genders

18+ years

Phase:

PHASE2

Brief Summary

This is a study for patients with head and neck cancer who will be receiving chemotherapy and radiation therapy for their disease. The purpose of this study is to see if the investigators can use gene...

Detailed Description

Treatment-naive patients with locally advanced, non-metastatic (Stage III to IVB) squamous cell carcinoma of the head and neck who are candidates for concurrent chemoradiotherapy as primary therapy wi...

Eligibility Criteria

Inclusion

  • Biopsy proven squamous cell carcinoma of the head and neck, including of the oral cavity, oropharynx, hypopharynx, or larynx
  • Locally advanced, Stage III or IVB disease and a candidate for primary therapy using chemotherapy and radiation with curative intent
  • Patients with a diagnosis of 'unknown primary' will be eligible if chemoradiotherapy is primary modality of treatment
  • No previous chemotherapy, radiation, or surgery for the diagnosis of head and neck cancer
  • ECOG performance status 0 or 1
  • Negative pregnancy test
  • Hemoglobin \>/= 8.0
  • Absolute neutrophil count \>/= 1500
  • Platelet count \>/= 100,000
  • GFR \> 50 mL/min
  • Total bilirubin \</= 1.5 upper limits of normal
  • AST and ALT \</= 2.5 times upper limits of normal
  • No other current malignancy, other than basal cell skin cancer, squamous cell skin cancer, in situ cervical cancer, ductal or lobular in situ of the breast.
  • Ability and willingness to give consent
  • Subjects must in the opinion of the Investigator be capable of complying with the protocol

Exclusion

  • Primary tumors of the nasopharynx, sinuses, and salivary glands
  • Acute treatment for an infection or other serious medical illness within 14 days prior to study entry
  • Major surgery within 3 weeks prior to study entry
  • Known hypersensitivity to cisplatin or cetuximab
  • Patients who have any severe or uncontrolled medical conditions or other conditions that could affect their participation in this study including: unstable angina, serious uncontrolled cardiac arrhythmia, active or uncontrolled infectious disorder, myocardial infarction \</= 6 months prior to study entry
  • Psychiatric illness that would limit compliance with study requirements

Key Trial Info

Start Date :

April 1 2009

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

June 1 2013

Estimated Enrollment :

Patients enrolled

Trial Details

Trial ID

NCT00881114

Start Date

April 1 2009

End Date

June 1 2013

Last Update

March 27 2015

Active Locations (0)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 0 (0 locations)

No Results Found

We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.